Nordea Investment Management AB held its position in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,693 shares of the medical device company’s stock at the end of the second quarter. Nordea Investment Management AB’s holdings in DexCom were worth $197,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in DXCM. UBS Asset Management Americas Inc. lifted its stake in DexCom by 14.1% in the 1st quarter. UBS Asset Management Americas Inc. now owns 248,178 shares of the medical device company’s stock worth $21,028,000 after purchasing an additional 30,737 shares in the last quarter. Karp Capital Management Corp purchased a new position in DexCom in the 1st quarter worth approximately $631,000. KBC Group NV lifted its stake in DexCom by 35.5% in the 1st quarter. KBC Group NV now owns 8,308 shares of the medical device company’s stock worth $704,000 after purchasing an additional 2,177 shares in the last quarter. SG Americas Securities LLC lifted its stake in DexCom by 25.3% in the 1st quarter. SG Americas Securities LLC now owns 8,557 shares of the medical device company’s stock worth $725,000 after purchasing an additional 1,729 shares in the last quarter. Finally, Credit Agricole S A lifted its stake in DexCom by 17.5% in the 1st quarter. Credit Agricole S A now owns 8,899 shares of the medical device company’s stock worth $754,000 after purchasing an additional 1,326 shares in the last quarter.
Shares of DexCom, Inc. (DXCM) opened at 46.84 on Friday. The stock’s market cap is $4.05 billion. The firm has a 50-day moving average price of $64.53 and a 200-day moving average price of $71.13. DexCom, Inc. has a 12 month low of $42.62 and a 12 month high of $88.80.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million for the quarter, compared to the consensus estimate of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. DexCom’s revenue was up 24.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.24) earnings per share. Equities analysts expect that DexCom, Inc. will post ($0.80) EPS for the current fiscal year.
DXCM has been the topic of a number of research reports. Northland Securities lowered shares of DexCom from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $85.00 to $60.00 in a research note on Thursday, September 28th. Robert W. Baird reissued a “hold” rating and issued a $79.00 target price on shares of DexCom in a research note on Sunday, September 10th. Wedbush reissued an “outperform” rating and issued a $76.00 target price (down from $85.00) on shares of DexCom in a research note on Thursday, September 28th. BidaskClub raised shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Finally, Barclays PLC initiated coverage on shares of DexCom in a research note on Friday, September 15th. They issued an “equal weight” rating and a $76.00 target price on the stock. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $72.19.
In other news, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $69.81, for a total value of $101,224.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Andrew K. Balo sold 3,244 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $71.18, for a total transaction of $230,907.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,023 shares of company stock worth $1,625,018. 1.70% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: “Nordea Investment Management AB Maintains Position in DexCom, Inc. (DXCM)” was originally reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2017/10/13/nordea-investment-management-ab-maintains-position-in-dexcom-inc-dxcm.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.